ARPA-H awards Linnaeus $22M to test LNS8801 for healthspan preservation in the PROSPR trial

Linnaeus Therapeutics/LNS8801

The U.S. Advanced Research Projects Agency for Health (ARPA-H) awarded Linnaeus Therapeutics up to $22 million to conduct the PROSPR trial, which will assess whether LNS8801 can preserve Intrinsic Capacity—the physical and cognitive abilities underlying independence—in healthy older adults.